SCHEMBL3594707

SCHEMBL3594707

Cc1ccc(-c2cccc3ccn(CC(=O)NCCNCC4CCCCC4)c23)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 3/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 2/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 2/20 0.39
CNR1 P21554 1/20 0.39
NPY5R Q15761 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 5/20 0.37
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
MMP13 P45452 1/20 0.36
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597289 0.91 ALDH1A1 (0.41) NPC1RAB9ALMNAMAPK1TSHR
SCHEMBL3608180 0.91 HTT (0.45) NPC1RAB9ALMNAMAPK1TSHR
SCHEMBL3608260 0.91 GRIN2B (0.42) NPC1RAB9ALMNAMAPK1TSHR
SCHEMBL3605921 0.90 EPHX2 (0.41) NPC1RAB9AKMT2ANPY5RALDH1A1
SCHEMBL3589653 0.89 ROCK2 (0.38) NPC1LMNAMAPK1TSHRALOX15
SCHEMBL3605625 0.88 MGLL (0.38) LMNAMAPK1NPY5RALDH1A1HSD17B10
SCHEMBL3589635 0.86 NPY5R (0.41) MAPK1TSHRKMT2ANPY5RALDH1A1
SCHEMBL3591246 0.86 LMNA (0.46) NPC1RAB9ALMNAMAPK1TSHR
SCHEMBL3596540 0.86 HSD17B10 (0.37) NPC1RAB9ALMNAMAPK1TSHR
SCHEMBL3605994 0.85 PIM1 (0.42) NPC1RAB9AMAPK1KMT2ANPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 NPC1 334/4885RAB9A 602/4885LMNA 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.